Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.

Julian PanesSéverine VermeireMarla C DubinskyEdward V LoftusNervin LawendyWenjin WangLeonardo SaleseChinyu SuIrene ModestoXiang GuoJean Frederic Colombel

Published in: Journal of Crohn's & colitis (2022)

Median time to treatment failure was numerically higher in induction remitters versus induction responders but non-remitters. Following treatment interruption, efficacy was safely and successfully recaptured with tofacitinib 10 mg b.d. re-treatment in a substantial proportion of patients [ClinicalTrials.gov:NCT01458574;NCT01470612].

Keyphrases

clinical trial
ulcerative colitis
rheumatoid arthritis
end stage renal disease
study protocol